854267-93-9 Usage
Structure
Contains a cyclopropane ring and a boron-containing phenyl group
Organic chemistry
Used as a building block for the synthesis of various pharmaceuticals and agrochemicals
Ligand
Potential to act as a ligand for transition metal catalysis
Drug discovery
Studied for its potential applications in drug discovery and medicinal chemistry
Material science
Presence of boron in the molecule gives it interesting properties for use in materials science and polymer chemistry
Reactivity
May be reactive with certain reagents, particularly those that can form bonds with boron or break the cyclopropane ring
Appearance
Unknown, but likely a solid at room temperature based on molecular weight and structure
Solubility
Unknown, but may be soluble in organic solvents such as dichloromethane or tetrahydrofuran due to the presence of the phenyl group
Toxicity
Unknown, but caution should be exercised when handling due to its potential use in pharmaceuticals and agrochemicals
Hazards
Potential hazards may include flammability, irritants, or corrosives, depending on the specific reactivity of the compound
Synthesis
The synthesis of 1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]Cyclopropanecarboxamide likely involves multiple steps, including the formation of the cyclopropane ring and the attachment of the boron-containing phenyl group.
Check Digit Verification of cas no
The CAS Registry Mumber 854267-93-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,5,4,2,6 and 7 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 854267-93:
(8*8)+(7*5)+(6*4)+(5*2)+(4*6)+(3*7)+(2*9)+(1*3)=199
199 % 10 = 9
So 854267-93-9 is a valid CAS Registry Number.
854267-93-9Relevant academic research and scientific papers
REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE A AND B
-
, (2008/06/13)
The instant invention relates to compounds of formula I, diagrammed below, wherein R3, E, D and Y are defined in the application, which are useful as reversible inhibitors of monoamine oxidase-B and/or monoamine oxidase-A, and therefore useful to treat or prevent neurological diseases or conditions in mammals, preferably humans.
CATHEPSIN CYSTEINE PROTEASE INHIBITORS
-
Page/Page column 47, (2010/02/12)
This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of cathepsins K, L, S and B. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.
